Fayez Sarofim & CO Bristol Myers Squibb CO Transaction History

Fayez Sarofim & CO

$38.7 Billion
Q3 2024

A detailed history of Fayez Sarofim & CO transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Fayez Sarofim & CO holds 5,898 shares of BMY stock, worth $343,440. This represents 0.0% of its overall portfolio holdings.

Number of Shares

5,898

Previous 5,898 -0.0%

Holding current value

$343,440

Previous $244,000 25.0%

% of portfolio

0.0%

Previous 0.0%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$40.25 - $52.99 $331,982 - $437,061	-8,248 Reduced 58.31%	5,898 $244,000
Q1 2024 May 14, 2024	SELL	$47.98 - $54.4 $187,553 - $212,649	-3,909 Reduced 21.65%	14,146 $767,000
Q4 2023 Feb 14, 2024	SELL	$48.48 - $57.85 $44,019 - $52,527	-908 Reduced 4.79%	18,055 $926,000
Q3 2023 Nov 14, 2023	BUY	$57.89 - $64.73 $198,736 - $222,218	3,433 Added 22.11%	18,963 $1.1 Million
Q2 2023 Aug 14, 2023	BUY	$63.71 - $70.74 $81,102 - $90,052	1,273 Added 8.93%	15,530 $993,000
Q1 2023 May 11, 2023	BUY	$65.71 - $74.53 $12,682 - $14,384	193 Added 1.37%	14,257 $988,000
Q4 2022 Feb 13, 2023	BUY	$68.48 - $81.09 $53,551 - $63,412	782 Added 5.89%	14,064 $1.01 Million
Q3 2022 Nov 14, 2022	BUY	$0.13 - $76.84 $89 - $52,865	688 Added 5.46%	13,282 $944,000
Q2 2022 Aug 12, 2022	SELL	$72.62 - $79.98 $141,826 - $156,200	-1,953 Reduced 13.43%	12,594 $970,000
Q1 2022 May 16, 2022	SELL	$61.48 - $73.72 $518,276 - $621,459	-8,430 Reduced 36.69%	14,547 $1.06 Million
Q4 2021 Feb 11, 2022	BUY	$53.63 - $62.52 $261,821 - $305,222	4,882 Added 26.98%	22,977 $1.43 Million
Q3 2021 Nov 15, 2021	BUY	$59.17 - $69.31 $124,612 - $145,966	2,106 Added 13.17%	18,095 $1.07 Million
Q2 2021 Aug 13, 2021	SELL	$61.91 - $67.42 $70,701 - $76,993	-1,142 Reduced 6.67%	15,989 $1.07 Million
Q1 2021 May 13, 2021	SELL	$59.34 - $66.74 $72,810 - $81,889	-1,227 Reduced 6.68%	17,131 $1.08 Million
Q4 2020 Feb 11, 2021	SELL	$57.74 - $65.43 $32,680 - $37,033	-566 Reduced 2.99%	18,358 $1.14 Million
Q3 2020 Nov 13, 2020	SELL	$57.43 - $63.64 $162,354 - $179,910	-2,827 Reduced 13.0%	18,924 $1.14 Million
Q2 2020 Aug 11, 2020	BUY	$54.82 - $64.09 $94,948 - $111,003	1,732 Added 8.65%	21,751 $1.28 Million
Q1 2020 May 12, 2020	SELL	$46.4 - $67.43 $27,051 - $39,311	-583 Reduced 2.83%	20,019 $1.12 Million
Q4 2019 Feb 14, 2020	BUY	$49.21 - $64.19 $25,835 - $33,699	525 Added 2.61%	20,602 $1.32 Million
Q3 2019 Nov 13, 2019	SELL	$42.77 - $50.71 $11,761 - $13,945	-275 Reduced 1.35%	20,077 $1.02 Million
Q2 2019 Aug 09, 2019	SELL	$44.62 - $49.34 $80,494 - $89,009	-1,804 Reduced 8.14%	20,352 $923,000
Q1 2019 May 14, 2019	BUY	$45.12 - $53.8 $42,864 - $51,110	950 Added 4.48%	22,156 $1.06 Million
Q4 2018 Feb 13, 2019	SELL	$48.76 - $63.23 $81,916 - $106,226	-1,680 Reduced 7.34%	21,206 $1.1 Million
Q3 2018 Nov 14, 2018	BUY	$55.19 - $62.25 $52,430 - $59,137	950 Added 4.33%	22,886 $1.42 Million
Q2 2018 Aug 14, 2018	SELL	$50.53 - $62.98 $170,437 - $212,431	-3,373 Reduced 13.33%	21,936 $1.21 Million
Q1 2018 May 10, 2018	BUY	$59.92 - $68.98 $26,364 - $30,351	440 Added 1.77%	25,309 $1.6 Million
Q4 2017 Feb 13, 2018	BUY	$59.94 - $65.35 $108,791 - $118,610	1,815 Added 7.87%	24,869 $1.52 Million
Q3 2017 Nov 08, 2017	BUY	$55.23 - $63.74 $1.27 Million - $1.47 Million	23,054	23,054 $1.47 Million

Others Institutions Holding BMY

# of Institutions

2,533

Shares Held

1.47B

Call Options Held

31.6M

Put Options Held

35M

View Full List

About BRISTOL MYERS SQUIBB CO

Ticker BMY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 2,126,160,000
Market Cap $124B
Description
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...

More about BMY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Fayez Sarofim & CO, based on Form 13F filings with the SEC.

News

Stay updated on Fayez Sarofim & CO with notifications on news.

Account